[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tiziana Life Sciences Plc (TILS.LN)

Tiziana Life Sciences Plc (TILS.LN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [LSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tiziana Life Sciences Plc 2 Church Street Clarendon House Hamilton HM 11 BMU

https://www.tizianalifesciences.com P: 207-495-2379

Sector:

N/A

INDUSTRY GROUPING:

N/A

Description:

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Key Statistics

Overview:

Market Capitalization, $K 113,848
Shares Outstanding, K 194,612
% of Insider Shareholders 36.97%
% of Institutional Shareholders 0.08%

Financials:

Annual Sales, $ 0 K
Annual Net Income, $ -18,431 K

Growth:

1-Year Return -65.79%
3-Year Return -38.26%
5-Year Return -68.97%
5-Year Revenue Growth 0.00%

Per-Share Information:

Next Earnings Date N/A
Earnings Per Share ttm -0.17
Dividend Payout Ratio 0.00%
Most Recent Split 1-300 on 04/24/14

TILS.LN Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Return-on-Equity % -924.32%
Return-on-Assets % -161.82%
Profit Margin % 0.00%
Debt/Equity 4.50
Price/Sales N/A
Price/Book 3.23
Book Value/Share 0.18
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.